Table 3.
Treatment-related immune adverse events (irAEs)
| AA (n=21) | non-AA (n=46) | All patients (n=67) | |||
|---|---|---|---|---|---|
|
| |||||
| Any irAE | |||||
| # of patients - n (%) | 8 (38) | 18 (39) | 26 (39) | ||
| # of episodes* | 15 | 26 | 44 | ||
|
| |||||
| Serious irAE (grade ≥3 or requiring treatment interruption and/or systemic corticosteroids) | 5 (24) | 9 (20) | 14 (21) | ||
|
| |||||
| irAEs | All grades | grades ≥3 | All grades | grades ≥3 | Total |
|
| |||||
| Dermatitis | 2 | 0 | 11 | 0 | 13 |
| Hypothyroidism | 5 | 0 | 5 | 0 | 10 |
| Hyperthyroidism | 2 | 0 | 2 | 0 | 4 |
| Diabetes | 1 | 1 | 1 | 1 | 2 |
| Adrenal insufficiency | 0 | 0 | 1 | 0 | 1 |
| Colitis | 1 | 1 | 4 | 2 | 5 |
| Pneumonitis | 1 | 0 | 1 | 0 | 2 |
| Guillain Barre Syndrome (Miller-Fischer) | 1 | 1 | 0 | 0 | 1 |
| Inflammatory arthritis | 1 | 0 | 0 | 0 | 1 |
| Optic neuritis | 0 | 0 | 1 | 0 | 1 |
| Parotitis¥ | 1 | 0 | 1 | ||
*
10 patients experienced more than one irAE
¥
irAE without a grade